Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 309

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1

Open access
Boyer, Thomas D., Sanyal, Arun J., Wong, Florence, Frederick, R. Todd, Lake, John R., O’Leary, Jacqueline G., Ganger, Daniel, Jamil, Khurram, Pappas, Stephen Chris, Sigal, Samuel H., Munoz, Santiago J., Patel, Vishal, Kwo, Paul Y., Bajaj, Jasmohan S., Hassanein, Tarek I., Shetty, Kirti, Satoskar, Rohit, Reddy, K. Rajender, Mayo, Marlyn, Araya, Victor, Hashemi, Nikroo, Feyssa, Eyob, Rossaro, Lorenzo, Kravetz, David, Grewal, Priya, Subramanian, Ram, Korenblat, Kevin, Genyk, Yuri Stepanovich, Regenstein, Fredric, Buell, Joseph F., Shores, Nathan J., Emre, Sukru H., Duchini, Andrea, Zaman, Atif, Olivera-Martinez, Marco Antonio, Porayko, Michael K., Befeler, Alex S., Reddy, K. Gautham, Del Pilar Hernandez, Maria, Zucker, Stephen D., Vargas, Hugo E., Curry, Michael, Said, Adnan, Kowdley, Kris V., Box, Terry, Barnes, David Shields, Pépin, Marie Noëlle, Rudraraju, Madhavi, Angulo, Paul, Monsour, Howard P., Wolf, David, Howell, Charles, Regenstein, Fredric G., Sanchez, Antonio, Elbeshbeshy, Hany, Fallon, Michael B., Swales, Colin, Sass, David A., Sotil, Eva Urtasun, McGuire, Brendan, Gilroy, Richard K., Guerrero, Juan A., Wong, Mark N., Shaikh, Obaid, Gonzalez, Stevan, Kayali, Zeid · 2016 · Gastroenterology

Abstract

BACKGROUND & AIMS: Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of acute kidney injury characterized by rapid (<2 wk) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1. METHODS: Adult patients with cirrhosis, ascites, and HRS-1 (based on the 2007 International Club of Ascites criteria of rapidly deteriorating renal function) were assigned randomly to groups given intravenous terlipressin (1 mg, n = 97) or placebo (n = 99) every 6 hours with concomitant albumin. Treatment continued through day 14 unless the following occurred: confirmed HRS reversal (CHRSR, defined as 2 serum creatinine [SCr] values ≤1.5 mg/dL, at least 40 hours apart, on treatment without renal replacement therapy or liver transplantation) or SCr at or above baseline on day 4. The primary end point was the percentage of patients with confirmed CHRSR. Secondary end points included the incidence of HRS reversal (defined as at least 1 SCr value ≤1.5 mg/dL while on treatment), transplant-free survival, and overall survival. The study was performed at 50 investigational sites in the United States and 2 in Canada, from October 2010 through February 2013. RESULTS: Baseline demographic/clinical characteristics were similar between groups. CHRSR was observed in 19 of 97 patients (19.6%) receiving terlipressin vs 13 of 99 patients (13.1%) receiving placebo (P = .22). HRS reversal was achieved in 23 of 97 (23.7%) patients receiving terlipressin vs 15 of 99 (15.2%) receiving placebo (P = .13). SCr decreased by 1.1 mg/dL in patients receiving terlipressin and by only 0.6 mg/dL in patients receiving placebo (P < .001). Decreases in SCr and survival were correlated (r(2) = .882; P < .001). Transplant-free and overall survival were similar between groups. A significantly greater proportion of patients with CHRSR who received terlipressin survived until day 90 than patients who did not have CHRSR after receiving terlipressin (P < .001); this difference was not observed in patients who did vs did not have CHRSR after receiving placebo (P = .28). There were similar numbers of adverse events in each group, but patients in the terlipressin group had more ischemic events. CONCLUSIONS: Terlipressin plus albumin was associated with greater improvement in renal function vs albumin alone in patients with cirrhosis and HRS-1. Patients had similar rates of HRS reversal with terlipressin as they did with albumin. ClinicalTrials.gov no: NCT01143246.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2016.02.026

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

Metadata

Authors
Boyer, T. D., Sanyal, A. J., Wong, F., Frederick, R. T., Lake, J. R., O’Leary, J. G., Ganger, D., Jamil, K., Pappas, S. C., Sigal, S. H., Munoz, S. J., Patel, V., Kwo, P. Y., Bajaj, J. S., Hassanein, T. I., Shetty, K., Satoskar, R., Reddy, K. R., Mayo, M., Araya, V., Hashemi, N., Feyssa, E., Rossaro, L., Kravetz, D., Grewal, P., Subramanian, R., Korenblat, K., Genyk, Y. S., Regenstein, F., Buell, J. F., Shores, N. J., Emre, S. H., Duchini, A., Zaman, A., Olivera-Martinez, M. A., Porayko, M. K., Befeler, A. S., Reddy, K. G., Del Pilar Hernandez, M., Zucker, S. D., Vargas, H. E., Curry, M., Said, A., Kowdley, K. V., Box, T., Barnes, D. S., Pépin, M. N., Rudraraju, M., Angulo, P., Monsour, H. P., Wolf, D., Howell, C., Regenstein, F. G., Sanchez, A., Elbeshbeshy, H., Fallon, M. B., Swales, C., Sass, D. A., Sotil, E. U., McGuire, B., Gilroy, R. K., Guerrero, J. A., Wong, M. N., Shaikh, O., Gonzalez, S., & Kayali, Z.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2016-06
Volume
150
Issue
7
Pages
1579-1589.e2
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2282617728
Cited by
309
References
26
FWCI
17.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.